[Ganciclovir treatment of congenital cytomegalovirus infection]

Area of Science:

• Virology
• Neonatal Medicine
• Pharmacology

Background:

• Congenital cytomegalovirus (CMV) infection is a significant cause of neonatal morbidity, particularly when affecting the central nervous system.
• Symptomatic congenital CMV infections require effective therapeutic interventions to prevent long-term sequelae.
• Ganciclovir is an antiviral medication with activity against cytomegalovirus.

Observation:

• Two infants with symptomatic congenital CMV infection involving the central nervous system were treated with intravenous ganciclovir.
• Treatment involved two phases of ganciclovir administration over 4 and 6 weeks at a daily dose of 5-10 mg/kg.
• Diagnosis and treatment monitoring utilized quantitative PCR assays for viral nucleic acid in blood and urine.

Findings:

• Ganciclovir treatment led to a substantial reduction in viral loads in both blood and urine samples.
• Significant clinical improvement was observed, especially in the infant with severe liver involvement, alongside biochemical marker improvements.
• While viral loads increased post-treatment, clinical symptoms did not recur, and one patient showed considerable improvement in hearing loss.

Implications:

• Ganciclovir therapy for neonatal CMV infection appears to be a promising strategy for disease progression prevention.
• Early intervention with ganciclovir may ameliorate the long-term consequences of congenital CMV infection.
• These findings support further investigation into ganciclovir's role in managing congenital CMV disease.